



Angiogenesis Inhibitors

Guest Editor:

Dr. Domenico Ribatti

Department of Basic Medical
Sciences, Neurosciences and
Sensory Organs, University of Bari
Medical School, Policlinico -
Piazza G. Cesare, 11, 70124 Bari,
Italy

domenico.ribatti@uniba.it

Deadline for manuscript
submissions:

closed (30 April 2011)

Message from the Guest Editor

Dear Colleagues,

The idea of targeting angiogenesis to inhibit tumor growth was proposed more than three decades ago by Judah Folkman, and since then several approaches to block or disrupt tumor angiogenesis have been explored.

Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.

Until now, the success of antiangiogenic compounds in the clinic is rather limited when given as monotherapies. This is in contrast with many preclinical results which revealed a much higher efficacy of these agents in animal models.

Prof. Dr. Domenico Ribatti
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access:—free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: Covered in the [Science Citation Index Expanded](#) - SCIE (Web of Science) from Vol. 10 (2017), as well as Embase and [Scopus](#). Citations available in [PubMed](#), full-text archived in [PubMed Central](#).

CiteScore (2019 Scopus data): 5.4, which equals rank 34/169 (Q1) in 'Pharmaceutical Science' and rank 68/165 (Q2) in 'Molecular Medicine'.

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com